Sanctuary Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Sanctuary Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$945K	Sell	3,139 -2,700	-46%	-$814K	﹤0.01%	1489
2026 Q1	$1.93M	Sell	5,839 -681	-10%	-$232K	0.01%	973
2025 Q4	$2.59M	Buy	6,520 +345	+6%	+$153K	0.01%	792
2025 Q3	$2.82M	Buy	6,175 +2,103	+52%	+$856K	0.02%	733
2025 Q2	$1.33M	Buy	4,072 +782	+24%	+$216K	0.01%	1054
2025 Q1	$888K	Sell	3,290 -1,625	-33%	-$418K	0.01%	1188
2024 Q4	$1.36M	Buy	4,915 +357	+8%	+$93.9K	0.01%	1074
2024 Q3	$1.12M	Buy	4,558 +2,181	+92%	+$568K	0.01%	1195
2024 Q2	$341K	Buy	+2,377	New	+$375K	﹤0.01%	1889

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sanctuary Advisors's ALNY Position: Q2 2026 in Review

Sanctuary Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 46% in Q2 2026, selling an estimated $814K and leaving 3,139 shares worth $945K. The position accounts for ﹤0.01% of the portfolio, ranked #1489.

Sanctuary Advisors first reported a position in ALNY in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.82M in Q3 2025. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Sanctuary Advisors held 3,139 shares of Alnylam Pharmaceuticals worth $945K as of Q2 2026.
Sanctuary Advisors sold 2,700 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $814K.
Alnylam Pharmaceuticals made up ﹤0.01% of Sanctuary Advisors's portfolio in Q2 2026, its #1489 holding.
Sanctuary Advisors first reported a position in Alnylam Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Sanctuary Advisors's Alnylam Pharmaceuticals position peaked at $2.82M in Q3 2025.
788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Sanctuary Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.